We speculate that reports of reduced cell proliferation or tumour growth following MCT inhibition are a product of toxic levels of cytoplasmic lactate build-up [40] or possibly off-target effects [1, 9, 10, 41], rather than glycolytic blockade per se. The gene discussed is SLC16A1; the disease is neoplasm.